Garomefrine hydrochlorid (ABT-232) is an α1A-adrenergic agonist with the potential to inhibit urinary incontinence. Garomefrine hydrochlorid showed the greatest contractility in pig nasal mucosal vessels. The biological activity of Garomefrine hydrochlorid has been shown to give it a competitive advantage compared to other drugs. The potency of Garomefrine hydrochlorid makes it a valuable research object in related research[1].
ChEBI: Garomefrine hydrochloride is a hydrochloride obtained by reaction of garomefrine with one equivalent of hydrochloric acid. It is a alpha1A adrenoreceptor agonist which was being developed for the treatment of urinary incontinence (now discontinued). It has a role as an alpha-adrenergic agonist and a nasal decongestant. It contains a garomefrine(1+).
[1] alpha(1)-adrenoceptor subtypes and effect of alpha(1A)-adrenoceptor agonist NS-49 on guinea pig nasal mucosa vasculature
